Neoleukin Therapeutics Inc.’s recent filing unveils that its Director BAKER BROS. ADVISORS LP acquired Company’s shares for reported $0.12 million on Aug 17. In the deal valued at $0.69 per share,166,942 shares were bought. As a result of this transaction, BAKER BROS. ADVISORS LP now holds 5,612,949 shares worth roughly $ 4.21 million.
Then, BAKER BROS. ADVISORS LP bought 229,600 shares, generating $156,254 in total proceeds. Upon buying the shares at $0.68, the Director now owns 5,458,724 shares.
Before that, BAKER BROS. ADVISORS LP bought 1,888,800 shares. Neoleukin Therapeutics Inc. shares valued at $1,191,616 were divested by the Director at a price of $0.63 per share. As a result of the transaction, BAKER BROS. ADVISORS LP now holds 5,246,614 shares, worth roughly $3.93 million.
PT values the company’s stock at a premium of 97.5 to its Friday closing price.
Price Performance Review of NLTX
On Friday, Neoleukin Therapeutics Inc. [NASDAQ:NLTX] saw its stock fall -0.27% to $0.75. On the same session, the stock had its day’s lowest price of $0.7391, but rose to a high of $0.81. Over the last five days, the stock has gained 4.42%. Neoleukin Therapeutics Inc. shares have risen nearly 47.54% since the year began. Nevertheless, the stocks have fallen -27.09% over the past one year. While a 52-week high of $1.10 was reached on 07/17/23, a 52-week low of $0.38 was recorded on 01/03/23. SMA at 50 days reached $0.7365, while 200 days put it at $0.6675. A total of 0.37 million shares were traded, compared to the trading of 0.33 million shares in the previous session.
Levels Of Support And Resistance For NLTX Stock
The 24-hour chart illustrates a support level at 0.7234, which if violated will result in even more drops to 0.6958. On the upside, there is a resistance level at 0.7943. A further resistance level may holdings at 0.8376. The Relative Strength Index (RSI) on the 14-day chart is 58.31, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0142, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 29.65%. Stochastics %K at 70.84% indicates the stock is a holding.
How much short interest is there in Neoleukin Therapeutics Inc.?
A steep rise in short interest was recorded in Neoleukin Therapeutics Inc. stocks on Aug 14, 2023, dropping by 94960.0 shares to a total of 0.13 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.22 million shares. There was a decline of -74.2%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.29% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.22.
According to FactSet, Neoleukin Therapeutics Inc.’s share price will average $1.50 in the next year, based on opinions of analysts polled by the firm. This is up nearly 100.0 percent from its previous closing price of $0.75. Analysts expect Neoleukin Therapeutics Inc. stock to reach the higher price of $1.50, while the lowest price estimate is $1.50. However, 1 analyst have rated NLTX stock as a Hold in their predictions for 2023.